全球 Xgeva 市場按適應症、年齡層、銷售管道、最終用戶和地區分類

預計 2025 年全球 Xgeva 市場規模為 22.721 億美元，2032 年將達到 31.407 億美元，2025 年至 2032 年的複合年成長率為 2.7%。

Xgeva 的全球市場代表製藥業的一個重要領域，主要集中在基於Denosumab的療法，用於治療癌症患者的骨相關併發症。 Xgeva（Denosumab）是一種人源單株抗體，作為 RANK 配體抑制劑，可有效預防固體癌骨轉移患者的骨骼相關事件，並治療骨鉅細胞瘤。由於全球癌症發生率的不斷上升以及人們對癌症治療中骨骼健康管理的認知不斷提高，這一專業治療領域正受到廣泛關注。

這個市場擁有各種各樣的相關人員，包括製藥商、醫療保健提供者、經銷商和監管機構，所有這些都構成了圍繞這一重要藥物的複雜生態系統。隨著全球醫療保健系統將全面的癌症治療放在首位，對像Xgeva這樣的有效骨骼保護療法的需求持續成長。市場動態受到監管部門核准、新興臨床證據、定價壓力以及生物相似藥替代品的出現等因素的影響。了解全球Xgeva市場的複雜格局對於製藥公司、醫療保健投資者和醫療專業人員來說至關重要，他們正試圖探索癌症治療方案中不斷變化的骨骼併發症治療方案。

市場動態

Xgeva 全球市場成長的關鍵驅動力在於全球癌症發生率的上升，這是由於固體癌數量不斷增加，而這些實體瘤通常會轉移到骨骼，從而對有效的骨保護療法產生了巨大的需求。此外，Denosumab的適應症已從骨轉移擴展到骨鉅細胞瘤和其他骨骼疾病，從而持續擴大了可及的患者群體。已開發地區醫療基礎設施的建設以及癌症專科治療可近性的提高，進一步推動了市場的成長。

然而，市場面臨著許多限制因素，包括高昂的治療費用限制了藥物的可近性，尤其是在價格敏感型市場和醫療預算受限的新興經濟體。長期使用Denosumab的安全隱患以及潛在的副作用，例如下顎骨壞死和非典型骨折，可能會導致製劑設計師猶豫不決，並面臨監管審查，從而阻礙市場擴張。此外，替代生物相似藥的出現也為安加維 (Xgeva) 品牌產品帶來了定價壓力和市場佔有率流失風險。儘管存在這些挑戰，但仍存在著巨大的機遇，例如透過持續的研發活動擴大臨床應用、與新型癌症療法的潛在聯合治療以及向醫療保健可及性不斷改善的未開發市場進行地域擴張。對個人化醫療和生物標記指導的治療選擇的日益關注，為市場成長提供了更多機會，而製藥公司和醫療保健提供者之間的戰略夥伴關係則有可能提升市場滲透率和患者可及性。

本次調查的主要特點

• 本報告對全球 Xgeva 市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的主要考察。
• 它根據公司亮點、產品系列、關鍵亮點、業績和策略等參數對全球 Xgeva 市場的主要企業進行了概述。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、最新策略、市場擴張和行銷策略做出明智的決策。
• Xgeva 的全球市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 透過全球 Xgeva 市場分析中使用的各種策略矩陣，相關人員可以輕鬆做出決策。

目錄

第1章：調查目標和先決條件

• 調查目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、法規與趨勢分析

• 市場動態
• 驅動程式
• 抑制因素
• 機會
• 影響分析
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景
• 產業趨勢
• 流行病學

4.全球Xgeva 市場（依適應症分類），2020 年至 2032 年

• 介紹
• 固態腫瘤骨轉移
• 骨鉅細胞瘤
• 雙磷酸鹽抗藥性癌症相關高血鈣症

5. 2020 年至 2032 年按年齡分類的全球 Xgeva 市場

• 介紹
• 成人
• 老年人
• 青年

6.全球Xgeva 市場依銷售管道分類，2020 年至 2032 年

• 介紹
• 線上
• 離線

7.全球Xgeva 市場（以最終用戶分類），2020 年至 2032 年

• 介紹
• 醫院
• 腫瘤中心
• 復健中心
• 其他（護理設施等）

8. 2020 年至 2032 年全球 Xgeva 市場（按地區分類）價值（百萬美元）

• 介紹
• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 東南亞國協
  • 其他亞太地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
• 非洲
  • 南非
  • 北非
  • 中部非洲

第9章 競爭態勢

• Amgen Inc.
• BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.

第 10 章分析師建議

• 機會
• 一致的機會地圖

第 11 章參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global Xgeva Market is estimated to be valued at USD 2,272.1 Mn in 2025 and is expected to reach USD 3,140.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 2.7% from 2025 to 2032.

The global Xgeva market represents a critical segment within the pharmaceutical industry, focusing on denosumab-based therapeutics primarily used for bone-related complications in cancer patients. Xgeva (denosumab) is a human monoclonal antibody that functions as a RANK ligand inhibitor, effectively preventing skeletal-related events in patients with bone metastases from solid tumors and treating giant cell tumor of bone. This specialized therapeutic area has garnered significant attention due to the increasing prevalence of cancer worldwide and the growing recognition of bone health management in oncology care.

The market encompasses various stakeholders, including pharmaceutical manufacturers, healthcare providers, distributors, and regulatory bodies, all contributing to the complex ecosystem surrounding this vital medication. As healthcare systems globally prioritize comprehensive cancer care, the demand for effective bone protection therapies like Xgeva continues to expand. The market dynamics are influenced by factors such as regulatory approvals, clinical evidence generation, pricing pressures, and the emergence of biosimilar alternatives. Understanding the intricate landscape of the Global Xgeva Market is essential for pharmaceutical companies, healthcare investors, and medical professionals seeking to navigate the evolving therapeutic options for bone complications in cancer treatment protocols.

Market Dynamics:

The global Xgeva market growth is primarily driven by the escalating global cancer burden, with increasing incidences of solid tumors that frequently metastasize to bone, creating substantial demand for effective bone protection therapies. The growing awareness among oncologists and healthcare providers regarding the importance of preventing skeletal-related events has significantly boosted market adoption, while expanding indications for denosumab beyond bone metastases to include giant cell tumor of bone and other bone disorders continues to broaden the addressable patient population. Advanced healthcare infrastructure in developed regions and improving access to specialty cancer care in emerging markets further propel market growth.

However, the market faces considerable restraints, including the high cost of treatment, which limits accessibility, particularly in price-sensitive markets and developing economies where healthcare budgets are constrained. Safety concerns and potential adverse effects associated with long-term denosumab use, including osteonecrosis of the jaw and atypical fractures, create prescriber hesitancy and regulatory scrutiny that can impede market expansion. Additionally, the emergence of biosimilar alternatives poses pricing pressure and market share erosion risks for branded Xgeva products. Despite these challenges, significant opportunities exist in the form of expanding clinical applications through ongoing research and development activities, potential combination therapies with emerging cancer treatments, and geographical expansion into underserved markets with improving healthcare access. The increasing focus on personalized medicine and biomarker-driven treatment selection presents additional avenues for market growth, while strategic partnerships between pharmaceutical companies and healthcare providers can enhance market penetration and patient access programs.

Key features of the study:

• This report provides an in-depth analysis of the global Xgeva market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Xgeva market based on the following parameters: company highlights, product portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc. and BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Xgeva market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Xgeva market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Bone Metastasis from Solid Tumors
  • Giant Cell Tumor of Bone
  • Hypercalcemia of malignancy refractory to bisphosphonates
• Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Adult
  • Geriatric
  • Adolescents
• Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online
  • Offline
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals
  • Oncology Centers
  • Rehabilitation Centers
  • Others (Long-Term Care Facilities, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Amgen Inc.
  • BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Xgeva Market, By Indication
  • Global Xgeva Market, By Age Group
  • Global Xgeva Market, By Sales Channel
  • Global Xgeva Market, By End User
  • Global Xgeva Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends
• Epidemiology
  • Adherence
  • Persistence

4. Global Xgeva Market, By Indication, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bone Metastasis from Solid Tumors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Giant Cell Tumor of Bone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Hypercalcemia of malignancy refractory to bisphosphonates
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Xgeva Market, By Age Group, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Adolescents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Xgeva Market, By Sales Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Online
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Offline
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Xgeva Market, By End User, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Oncology Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Rehabilitation Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Long-Term Care Facilities, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Xgeva Market, By Region, 2020 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BeOne Medicines, Ltd, formerly known as BeiGene, Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us